News & Perspective

Nov 15, 2019

Nov 15, 2019

ASP Scan (Weekly) for Nov 15, 2019

Dental antibiotic stewardship
Host-response diagnostic tests
Antibiotic use, resistance in Europe
Pakistan and typhoid vaccine
Hospital stewardship toolkit
Candida auris in NY hospitals
Antibiotic prescribing drop in Finland
Scottish antibiotic use
Improper antibiotic Rx in Japan
Pre-op antibiotic overuse
Highly lethal Klebsiella strain
FDA antimicrobial guidance
C diff in VA hospitals
UK antibiotic development
ESBL carriage in dogs

Nov 23, 2018

Nov 23, 2018

ASP Scan (Weekly) for Nov 23, 2018

MDR Pseudomonas in Texas
Endoscope-linked MDRO outbreak
Pan-drug resistance in Ethiopia
Antibiotic use in NICUs
UK animal antibiotic use
Antimicrobial stewardship in Latin America, Caribbean
New antibiotic for travelers' diarrhea

Jul 17, 2017

Jul 17, 2017

News Scan for Jul 17, 2017

Cyclospora in Texas
Non-prudent abx use in Europe
MERS super spreader
Smallpox vaccine deal

Mar 01, 2012

Mar 01, 2012

FDA clears first quadrivalent flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the first quadrivalent influenza vaccine, an inhaled live attenuated influenza vaccine developed by MedImmune and modeled after its FluMist product.

The vaccine includes a second influenza B strain, which is designed to broaden protection against circulating strains. MedImmune plans to have the quadrivalent vaccine ready for the 2013-14 flu season.

Oct 06, 2010

Oct 06, 2010

Trial answers some, not all, questions on cell-based flu vaccines

(CIDRAP News) – A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»